GlaxoSmithKline Pharmaceuticals Limited

BSE:500660 Stock Report

Market Cap: ₹445.9b

GlaxoSmithKline Pharmaceuticals Valuation

Is 500660 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 500660 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 500660 (₹2632.2) is trading above our estimate of fair value (₹1074.89)

Significantly Below Fair Value: 500660 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 500660?

Other financial metrics that can be useful for relative valuation.

500660 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue11.9x
Enterprise Value/EBITDA42.5x
PEG Ratio3.9x

Price to Earnings Ratio vs Peers

How does 500660's PE Ratio compare to its peers?

The above table shows the PE ratio for 500660 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average76.1x
SUVENPHAR Suven Pharmaceuticals
140.2x31.1%₹337.0b
IPCALAB Ipca Laboratories
69.7x29.9%₹401.8b
AJANTPHARM Ajanta Pharma
44.5x16.3%₹389.1b
500488 Abbott India
49.9x9.8%₹618.7b
500660 GlaxoSmithKline Pharmaceuticals
66.1x16.8%₹445.9b

Price-To-Earnings vs Peers: 500660 is good value based on its Price-To-Earnings Ratio (66.1x) compared to the peer average (76.1x).


Price to Earnings Ratio vs Industry

How does 500660's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.5%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.5%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 500660 is expensive based on its Price-To-Earnings Ratio (66.1x) compared to the Indian Pharmaceuticals industry average (39x).


Price to Earnings Ratio vs Fair Ratio

What is 500660's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

500660 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio66.1x
Fair PE Ratio42.7x

Price-To-Earnings vs Fair Ratio: 500660 is expensive based on its Price-To-Earnings Ratio (66.1x) compared to the estimated Fair Price-To-Earnings Ratio (42.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 500660 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹2,632.20
₹2,914.50
+10.7%
9.1%₹3,250.00₹2,550.00n/a4
Oct ’25₹2,738.45
₹2,908.75
+6.2%
9.7%₹3,250.00₹2,620.00n/a4
Sep ’25₹2,745.40
₹2,908.75
+5.9%
9.7%₹3,250.00₹2,620.00n/a4
Aug ’25₹2,755.90
₹2,694.25
-2.2%
11.6%₹3,012.00₹2,380.00n/a4
Jul ’25₹2,605.70
₹2,694.25
+3.4%
11.6%₹3,012.00₹2,380.00n/a4
Jun ’25₹2,630.60
₹2,598.50
-1.2%
11.1%₹3,000.00₹2,270.00n/a4
May ’25₹2,087.10
₹2,141.25
+2.6%
9.7%₹2,450.00₹1,895.00n/a4
Apr ’25₹1,987.45
₹2,141.25
+7.7%
9.7%₹2,450.00₹1,895.00n/a4
Mar ’25₹2,147.15
₹2,141.25
-0.3%
9.7%₹2,450.00₹1,895.00n/a4
Feb ’25₹2,226.75
₹1,783.80
-19.9%
19.5%₹2,450.00₹1,490.00n/a5
Jan ’25₹1,952.65
₹1,566.80
-19.8%
5.3%₹1,669.00₹1,480.00n/a5
Dec ’24₹1,677.05
₹1,566.80
-6.6%
5.3%₹1,669.00₹1,480.00n/a5
Nov ’24₹1,410.05
₹1,434.00
+1.7%
8.3%₹1,575.00₹1,215.00₹2,729.705
Oct ’24₹1,544.50
₹1,408.00
-8.8%
9.2%₹1,575.00₹1,215.00₹2,738.455
Sep ’24₹1,438.40
₹1,408.00
-2.1%
9.2%₹1,575.00₹1,215.00₹2,745.405
Aug ’24₹1,404.10
₹1,425.00
+1.5%
8.7%₹1,575.00₹1,215.00₹2,755.906
Jul ’24₹1,423.85
₹1,354.17
-4.9%
8.6%₹1,510.00₹1,215.00₹2,605.706
Jun ’24₹1,327.35
₹1,340.14
+1.0%
8.4%₹1,510.00₹1,215.00₹2,630.607
May ’24₹1,242.00
₹1,353.43
+9.0%
8.6%₹1,510.00₹1,145.00₹2,087.107
Apr ’24₹1,324.15
₹1,352.00
+2.1%
8.5%₹1,500.00₹1,145.00₹1,987.457
Mar ’24₹1,334.50
₹1,380.57
+3.5%
7.7%₹1,500.00₹1,145.00₹2,147.157
Feb ’24₹1,250.75
₹1,484.00
+18.6%
9.6%₹1,690.00₹1,226.00₹2,226.757
Jan ’24₹1,318.90
₹1,518.29
+15.1%
13.4%₹1,930.00₹1,226.00₹1,952.657
Dec ’23₹1,322.70
₹1,518.29
+14.8%
13.4%₹1,930.00₹1,226.00₹1,677.057
Nov ’23₹1,378.75
₹1,597.14
+15.8%
13.1%₹1,930.00₹1,378.00₹1,410.057

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies